DK3292153T3 - Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling - Google Patents

Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling

Info

Publication number
DK3292153T3
DK3292153T3 DK16723968.0T DK16723968T DK3292153T3 DK 3292153 T3 DK3292153 T3 DK 3292153T3 DK 16723968 T DK16723968 T DK 16723968T DK 3292153 T3 DK3292153 T3 DK 3292153T3
Authority
DK
Denmark
Prior art keywords
antibody
cd30xcd16a
treatment
combination
antagonistic
Prior art date
Application number
DK16723968.0T
Other languages
Danish (da)
English (en)
Inventor
Martin Treder
Uwe Reusch
Jens-Peter Marschner
Stefan Knackmuss
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15166303.6A external-priority patent/EP3091031A1/en
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Application granted granted Critical
Publication of DK3292153T3 publication Critical patent/DK3292153T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16723968.0T 2015-05-04 2016-05-04 Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling DK3292153T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166303.6A EP3091031A1 (en) 2015-05-04 2015-05-04 Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP16152650 2016-01-25
PCT/EP2016/060113 WO2016177846A1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Publications (1)

Publication Number Publication Date
DK3292153T3 true DK3292153T3 (da) 2019-10-21

Family

ID=56026814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16723968.0T DK3292153T3 (da) 2015-05-04 2016-05-04 Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling

Country Status (20)

Country Link
US (1) US11167029B2 (https=)
EP (1) EP3292153B1 (https=)
JP (1) JP6609784B2 (https=)
CN (1) CN107847587B (https=)
AU (1) AU2016257334B2 (https=)
BR (1) BR112017023579A2 (https=)
CA (2) CA3219372A1 (https=)
CY (1) CY1122283T1 (https=)
DK (1) DK3292153T3 (https=)
ES (1) ES2754557T3 (https=)
HR (1) HRP20191933T1 (https=)
HU (1) HUE045866T2 (https=)
LT (1) LT3292153T (https=)
PL (1) PL3292153T3 (https=)
PT (1) PT3292153T (https=)
RS (1) RS59489B1 (https=)
RU (1) RU2761352C2 (https=)
SI (1) SI3292153T1 (https=)
SM (1) SMT201900598T1 (https=)
WO (1) WO2016177846A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018226526B2 (en) 2017-02-28 2025-03-13 Affimed Gmbh Combination of an anti-CD16A antibody with a cytokine
WO2018158349A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
BR112020018492A2 (pt) 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
HRP20240821T1 (hr) * 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
JP2022536684A (ja) * 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
AU2020414409A1 (en) * 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JP2024503933A (ja) * 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
WO2023274183A1 (zh) 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
EP4413039A1 (en) 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
CN118613271A (zh) * 2021-11-04 2024-09-06 埃迪瓦生物治疗公司 用nk细胞和多特异性接合子治疗癌症
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2611861C (en) * 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Also Published As

Publication number Publication date
JP2018514576A (ja) 2018-06-07
PT3292153T (pt) 2019-11-05
CN107847587A (zh) 2018-03-27
RU2761352C2 (ru) 2021-12-07
RS59489B1 (sr) 2019-12-31
CN107847587B (zh) 2020-10-09
LT3292153T (lt) 2019-11-11
US11167029B2 (en) 2021-11-09
JP6609784B2 (ja) 2019-11-27
AU2016257334B2 (en) 2021-08-12
BR112017023579A2 (pt) 2018-07-24
CY1122283T1 (el) 2020-11-25
ES2754557T3 (es) 2020-04-20
PL3292153T3 (pl) 2020-02-28
HUE045866T2 (hu) 2020-01-28
CA2983706A1 (en) 2016-11-10
CA3219372A1 (en) 2016-11-10
WO2016177846A1 (en) 2016-11-10
AU2016257334A1 (en) 2017-11-09
SI3292153T1 (sl) 2020-01-31
EP3292153A1 (en) 2018-03-14
US20180085456A1 (en) 2018-03-29
RU2017137251A3 (https=) 2019-10-10
HK1253022A1 (zh) 2019-06-06
HRP20191933T1 (hr) 2020-01-10
EP3292153B1 (en) 2019-07-31
RU2017137251A (ru) 2019-06-04
SMT201900598T1 (it) 2020-01-14
CA2983706C (en) 2024-01-02

Similar Documents

Publication Publication Date Title
DK3292153T3 (da) Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling
CY2025001I2 (el) Νεα αντι-pd-l1 αντισωματα
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
HUE051700T2 (hu) Anti-PD-1 antitestek
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3302565T3 (da) Faste doseringsformer af palbociclib
EP3334824A4 (en) PD-1 ANTIBODY
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3182975T3 (da) Tabletter med høj doseringsstyrke af rucaparib
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3114235T3 (da) Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet
DK3125942T3 (da) Forstøvning af immunoglobulin
DK3390422T3 (da) Krystalformer af lnt